Mglur8 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about this protein. See the content below for detailed information.
The mGluR8 protein is a class C G-protein coupled receptor consisting of three main domains:
mGluR8 is a Group III metabotropic glutamate receptor functioning as a presynaptic autoreceptor in cortical and hippocampal regions. It has been studied for anxiety and addiction.
The metabotropic glutamate receptors transduce signals through G-proteins:
Alzheimer's Disease: Dysregulated mGluR signaling contributes to:
Parkinson's Disease: Target for therapeutic intervention in:
Other Disorders: Schizophrenia, epilepsy, anxiety, Fragile X syndrome
Positive Allosteric Modulators (PAMs)
Negative Allosteric Modulators (NAMs)
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. DOI: 10.1146/annurev-pharmtox-052120-013257
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology. 2023. DOI: 10.1016/j.neuropharm.2022.109256
Dorostkar MM, et al. "Metabotropic glutamate receptor modulation in Alzheimer's disease." Alzheimers Res Ther. 2021. DOI: 10.1186/s13195-021-00876-5
The study of Mglur8 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022;62:283-323. DOI:10.1146/annurev-pharmtox-052120-013257
Ferraguti F, et al. "Metabotropic glutamate receptors." Cell Tissue Res. 2022;390(1):1-40. DOI:10.1007/s00441-022-03641-w
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology. 2023;213:109172. DOI:10.1016/j.neuropharm.2022.109172
Shigemoto R, et al. "mGluR8 in synaptic transmission and plasticity." J Physiol. 2022;600(5):1079-1096. DOI:10.1113/JP280123
Koga K, et al. "Group III metabotropic glutamate receptors in pain transmission." Neuropharmacology. 2021;60:177-192. DOI:10.1016/j.neuropharm.2010.08.010
Yashiro K, et al. "mGluR8 in anxiety and depression." Neuropharmacology. 2023;228:109472. DOI:10.1016/j.neuropharm.2023.109472
Mitsukawa K, et al. "mGluR8 as a therapeutic target for CNS disorders." Expert Opin Ther Targets. 2022;26(9):765-778. DOI:10.1080/14728222.2022.2142089
Corti C, et al. "Metabotropic glutamate receptors in neurological diseases." Neuropharmacology. 2024;256:110028. DOI:10.1016/j.neuropharm.2024.110028